Technical analysis of BioAtla, Inc. (BCAB): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer.
Price Performance
| 1 month | -53.77% |
| 3 months | -59.84% |
| Year-to-date | -94.82% |
| 1 year | -95.66% |
| 3 years | -98.49% |
| 5 years | -99.91% |
52-Week Range
| 52-week High | $71.50 |
| 52-week Low | $1.07 |
| Avg Volume (90d) | 67K |
Technical Indicators
| SMA 50 | $3.03 |
| SMA 200 | $10.58 |
| 30-day Volatility (annualised) | 230.3% |
| Price vs SMA 50 | -51.5% |
| Price vs SMA 200 | -86.1% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $34.97 | |
| 2025-11 | $45.20 | +29.3% |
| 2025-12 | $28.39 | -37.2% |
| 2026-01 | $13.45 | -52.6% |
| 2026-02 | $12.37 | -8.0% |
| 2026-03 | $8.05 | -34.9% |
| 2026-04 | $4.21 | -47.7% |
| 2026-05 | $3.93 | -6.7% |
| 2026-06 | $4.14 | +5.3% |
| 2026-07 | $3.29 | -20.5% |
| 2026-08 | $1.69 | -48.6% |
| 2026-09 | $1.47 | -13.0% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | $144M |
| 2026-09-14 | | $898M |
Price
| Price | $1.74 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -0.08 |
| EV / EBITDA | -0.25 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | -0.16 |
| Current Ratio | 0.20 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -70.06 |